190 related articles for article (PubMed ID: 18348746)
1. Bioequivalence of recombinant human FSH and recombinant human LH in a fixed 2:1 combination: two phase I, randomised, crossover studies.
Picard M; Rossier C; Papasouliotis O; Lugan I
Curr Med Res Opin; 2008 Apr; 24(4):1199-208. PubMed ID: 18348746
[TBL] [Abstract][Full Text] [Related]
2. Administration of follitropin alfa and lutropin alfa combined in a single injection: a feasibility assessment.
Agostinetto R
Reprod Biol Endocrinol; 2009 May; 7():48. PubMed ID: 19450267
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders.
Humaidan P; Chin W; Rogoff D; D'Hooghe T; Longobardi S; Hubbard J; Schertz J;
Hum Reprod; 2017 Mar; 32(3):544-555. PubMed ID: 28137754
[TBL] [Abstract][Full Text] [Related]
4. Open-Label, Randomized, Two-Way, Crossover Study Assessing the Bioequivalence of the Liquid Formulation versus the Freeze-Dried Formulation of Recombinant Human FSH and Recombinant Human LH in a Fixed 2:1 Combination (Pergoveris
Bagchus W; Yalkinoglu Ö; Wolna P
Front Endocrinol (Lausanne); 2017; 8():371. PubMed ID: 29375477
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment.
Marrs R; Meldrum D; Muasher S; Schoolcraft W; Werlin L; Kelly E
Reprod Biomed Online; 2004 Feb; 8(2):175-82. PubMed ID: 14989794
[TBL] [Abstract][Full Text] [Related]
6. Follicular development induced by recombinant luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in anovulatory women with LH and FSH deficiency: evidence of a threshold effect.
O'Dea L; O'Brien F; Currie K; Hemsey G
Curr Med Res Opin; 2008 Oct; 24(10):2785-93. PubMed ID: 18727841
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of recombinant human FSH: recombinant human LH combination treatment versus recombinant human FSH alone for assisted reproductive technology in women aged 35-40 years.
Bielfeld AP; Schwarze JE; Verpillat P; Lispi M; Fischer R; Hayward B; Chuderland D; D'Hooghe T; Krussel JS
Reprod Biomed Online; 2024 Jun; 48(6):103725. PubMed ID: 38593745
[TBL] [Abstract][Full Text] [Related]
8. Bioequivalence of liquid and freeze-dried recombinant human follicle-stimulating hormone.
Lugan I; Febbraro S; Lecuelle H; Papasouliotis O; Ho-Nguyena Q; Buraglio M
Curr Med Res Opin; 2005 Jan; 21(1):121-5. PubMed ID: 15881483
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the biopotency of follitropin alfa and lutropin alfa combined in one injection: a comparative trial in Sprague-Dawley rats.
Alper M; Meyer R; Dekkers C; Ezcurra D; Schertz J; Kelly E
Reprod Biol Endocrinol; 2008 Jul; 6():31. PubMed ID: 18647398
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis.
Lehert P; Kolibianakis EM; Venetis CA; Schertz J; Saunders H; Arriagada P; Copt S; Tarlatzis B
Reprod Biol Endocrinol; 2014 Feb; 12():17. PubMed ID: 24555766
[TBL] [Abstract][Full Text] [Related]
11. The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double-blind, randomized, prospective study.
Tarlatzis B; Tavmergen E; Szamatowicz M; Barash A; Amit A; Levitas E; Shoham Z
Hum Reprod; 2006 Jan; 21(1):90-4. PubMed ID: 16172149
[TBL] [Abstract][Full Text] [Related]
12. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
[TBL] [Abstract][Full Text] [Related]
13. Safety of Follitropin Alfa/Lutropin Alfa for Stimulation of Follicular Development.
Abramova N; Hubbard J; Schertz J; Richter E
Drug Saf; 2019 Mar; 42(3):453-461. PubMed ID: 30341677
[TBL] [Abstract][Full Text] [Related]
14. Comparison of pharmacokinetic and safety profiles between Bemfola(®) and Gonal-f(®) after subcutaneous application.
Wolzt M; Gouya G; Sator M; Hemetsberger T; Irps C; Rettenbacher M; Vcelar B
Eur J Drug Metab Pharmacokinet; 2016 Jun; 41(3):259-65. PubMed ID: 25633239
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human LH supplementation versus supplementation with urinary hCG-based LH activity during controlled ovarian stimulation in the long GnRH-agonist protocol: a matched case-control study.
Bühler KF; Fischer R
Gynecol Endocrinol; 2012 May; 28(5):345-50. PubMed ID: 22115012
[TBL] [Abstract][Full Text] [Related]
16. Mid-follicular LH supplementation in women aged 35-39 years undergoing ICSI cycles: a randomized controlled study.
Matorras R; Prieto B; Exposito A; Mendoza R; Crisol L; Herranz P; Burgués S
Reprod Biomed Online; 2009 Dec; 19(6):879-87. PubMed ID: 20031032
[TBL] [Abstract][Full Text] [Related]
17. Phase I, two-way, crossover study to demonstrate bioequivalence and to compare safety and tolerability of single-dose XM17 vs Gonal-f® in healthy women after follicle-stimulating hormone downregulation.
Lammerich A; Mueller A; Bias P
Reprod Biol Endocrinol; 2015 Dec; 13():130. PubMed ID: 26621118
[TBL] [Abstract][Full Text] [Related]
18. Effects of recombinant LH treatment on folliculogenesis and responsiveness to FSH stimulation.
Durnerin CI; Erb K; Fleming R; Hillier H; Hillier SG; Howles CM; Hugues JN; Lass A; Lyall H; Rasmussen P; Thong J; Traynor I; Westergaard L; Yates R;
Hum Reprod; 2008 Feb; 23(2):421-6. PubMed ID: 18084048
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin) HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection. The French Multicentre Trialists.
Frydman R; Howles CM; Truong F
Hum Reprod; 2000 Mar; 15(3):520-5. PubMed ID: 10686190
[TBL] [Abstract][Full Text] [Related]
20. A direct healthcare cost analysis of recombinant LH versus hMG supplementation on FSH during controlled ovarian hyperstimulation in the GnRH-antagonist protocol.
Chang JC; Yi YC; Chen YF; Guu HF; Kung HF; Chen LY; Chuan ST; Chang YM; Chen MJ
Arch Gynecol Obstet; 2024 Feb; 309(2):699-706. PubMed ID: 38099955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
